Targeted blood-to-brain drug delivery - 10 key development criteria

Current Pharmaceutical Biotechnology

Volumn 13, Issue 12, 2012, Pages 2328-2339

  Gaillard, Pieter J ^a   Visser, Corine C ^a   Appeldoorn, Chantal C M ^a   Rip, Jaap ^a  

^a To BBB Technologies BV   (Netherlands)

Author keywords

Blood brain barrier; Brain diseases; CNS; Drug targeting; Receptor mediated endocytosis; Transport transcytosis

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN RECEPTOR; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; HYBRID PROTEIN; INSULIN RECEPTOR; LIPOPROTEIN RECEPTOR; LOPERAMIDE; METHOTREXATE; PACLITAXEL; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; NEUROPROTECTION; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84867717502     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112803341815     Document Type: Review

References (135)

1. Pardridge, W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3(2), 90-105.
2. Smith, M.W.; Gumbleton, M. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J. Drug Target, 2006, 14(4), 191-214.
3. Pardridge, W.M. Blood-brain barrier biology and methodology. J. Neurovirol., 1999, 5(6), 556-569.
4. Abbott, N.J. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol. Neurobiol., 2005, 25(1), 5-23.
5. de Boer, A.G.; Gaillard, P.J. Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet., 2007, 46(7), 553-576.
6. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
7. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2005, 2(1), 3-14.
8. Bidros, D.S.; Vogelbaum, M.A. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics, 2009, 6(3), 539-546.
9. Debinski, W.; Tatter, S.B. Convection-enhanced delivery for the treatment of brain tumors. Expert. Rev. Neurother., 2009, 9(10), 1519-1527.
10. Dickson, P.I. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int. J. Clin. Pharmacol. Ther., 2009, 47 (Suppl 1), S124-127.
11. Gaillard, P.J.; de Boer, A.G. A novel opportunity for targeted drug delivery to the brain. J. Control Release, 2006, 116(2), e60-62.
12. Pardridge, W.M. Drug and gene delivery to the brain: the vascular route. Neuron, 2002, 36(4), 555-558.
13. Gaillard, P.J.; Visser, C.C.; de Boer, A.G. Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv., 2005, 2(2), 299-309.
14. Bellavance, M.A.; Blanchette, M.; Fortin, D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS. J., 2008, 10(1), 166-177.
15. de Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 323-355.
16. de Boer, A.G.; van der Sandt, I.C.; Gaillard, P.J. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 629-656.
17. Pardridge, W.M. Brain drug development and brain drug targeting. Pharm. Res., 2007, 24(9), 1729-1732.
18. Pardridge, W.M. Drug targeting to the brain. Pharm. Res., 2007, 24(9), 1733-1744.
19. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37(1), 48-57.
20. Jones, A.R.; Shusta, E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res., 2007, 24(9), 1759-1771.
21. Rip, J.; Schenk, G.J.; de Boer, A.G. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv., 2009, 6(3), 227-237.
22. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46(1-3), 3-26.
23. Rubin, L.L.; Staddon, J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci., 1999, 22, 11-28.
24. van der Sandt, I.C.; de Boer, A.G.; Breimer, D.D. In: Blood-spinal cord and brain barriers in health and disease; Sharma, H.S.;Wesman, J., Eds. Elsevier Academic Press: San Diego. 2004, pp. 63-72.
25. Vorbrodt, A.W. Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. Neurocytol., 1989, 18(3), 359-368.
26. Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today, 1996, 2(3), 106-113.
27. Wade, L.A.; Katzman, R. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J. Neurochem., 1975, 25(6), 837-842.
28. Egleton, R.D.; Davis, T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 1997, 18(9), 1431-1439.
29. Qin, Y.; Fan, W.; Chen, H.; Yao, N.; Tang, W.; Tang, J.; Yuan, W.; Kuai, R.; Zhang, Z.; Wu, Y.; He, Q. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J. Drug Target, 2010.
30. Hu, K.; Li, J.; Shen, Y.; Lu, W.; Gao, X.; Zhang, Q.; Jiang, X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release, 2009, 134(1), 55-61.
31. Chen, H.; Tang, L.; Qin, Y.; Yin, Y.; Tang, J.; Tang, W.; Sun, X.; Zhang, Z.; Liu, J.; He, Q. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci., 2010.
32. Khare, P.; Jain, A.; Jain, N.K.; Soni, V.; Jain, S.K. Glutamateconjugated liposomes of dopamine hydrochloride for effective management of parkinsonism's. PDA. J. Pharm. Sci. Technol., 2009, 63(5), 372-379.
33. Kim, S.S.; Ye, C.; Kumar, P.; Chiu, I.; Subramanya, S.; Wu, H.; Shankar, P.; Manjunath, N. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol. Ther., 2010.
34. Kumar, P.; Wu, H.; McBride, J.L.; Jung, K.E.; Kim, M.H.; Davidson, B.L.; Lee, S.K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149), 39-43.
35. Liu, Y.; Huang, R.; Han, L.; Ke, W.; Shao, K.; Ye, L.; Lou, J.; Jiang, C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials, 2009, 30(25), 4195-4202.
36. Tosi, G.; Vergoni, A.V.; Ruozi, B.; Bondioli, L.; Badiali, L.; Rivasi, F.; Costantino, L.; Forni, F.; Vandelli, M.A. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J. Control. Release, 2010.
37. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; Vandelli, M.A.; Forni, F. Targeting the central nervous system: in vivo experiments with peptidederivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release, 2007, 122(1), 1-9.
38. Wang, Z.H.; Wang, Z.Y.; Sun, C.S.; Wang, C.Y.; Jiang, T.Y.; Wang, S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials, 2010, 31(5), 908-915.
39. Rao, K.S.; Reddy, M.K.; Horning, J.L.; Labhasetwar, V. TATconjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials, 2008, 29(33), 4429-4438.
40. Abulrob, A.; Sprong, H.; Van Bergen en Henegouwen, P.; Stanimirovic, D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem., 2005, 95(4), 1201-1214.
41. Chandra, S.; De, K.; Ganguly, S.; Sarkar, B.; Misra, M. Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivatives for potential nuclear medicine applications. Peptides, 2009, 30(12), 2399-2408.
42. Malakoutikhah, M.; Prades, R.; Teixido, M.; Giralt, E. N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttles. J. Med. Chem., 2010, 53(6), 2354-2363.
43. Plattner, V.E.; Germann, B.; Neuhaus, W.; Noe, C.R.; Gabor, F.; Wirth, M. Characterization of two blood-brain barrier mimicking cell lines: distribution of lectin-binding sites and perspectives for drug delivery. Int. J. Pharm, 2010, 387(1-2), 34-41.
44. Tamaru, M.; Akita, H.; Fujiwara, T.; Kajimoto, K.; Harashima, H. Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem. Biophys. Res. Commun., 2010, 394(3), 587-592.
45. Foucout, L.; Gourand, F.; Dhilly, M.; Bohn, P.; Dupas, G.; Costentin, J.; Abbas, A.; Marsais, F.; Barre, L.; Levacher, V. Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery. Org. Biomol. Chem., 2009, 7(18), 3666-3673.
46. van Rooy, I.; Cakir-Tascioglu, S.; Couraud, P.O.; Romero, I.A.; Weksler, B.; Storm, G.; Hennink, W.E.; Schiffelers, R.M.; Mastrobattista, E. Identification of peptide ligands for targeting to the blood-brain barrier. Pharm. Res., 2010, 27(4), 673-682.
47. Ponka, P.; Lok, C.N. The transferrin receptor: role in health and disease. Int. J. Biochem. Cell. Biol., 1999, 31(10), 1111-1137.
48. Moos, T.; Morgan, E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol. Neurobiol., 2000, 20(1), 77-95.
49. Zhang, Y.; Pardridge, W.M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J. Pharmacol. Exp. Ther., 2005, 313(3), 1075-1081.
50. Zhang, Y.; Pardridge, W.M. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res., 2006, 1111(1), 227-229.
51. Zhang, Y.; Wang, Y.; Boado, R.J.; Pardridge, W.M. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm. Res., 2008, 25(2), 400-406.
52. Boado, R.J.; Zhang, Y.; Wang, Y.; Pardridge, W.M. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng., 2009, 102(4), 1251-1258.
53. Boado, R.J.; Zhou, Q.H.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm., 2010, 7(1), 237-244.
54. Zhou, Q.H.; Boado, R.J.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. Drug Metab. Dispos., 2010, 38(4), 566-572.
55. Xia, C.F.; Zhang, Y.; Boado, R.J.; Pardridge, W.M. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res., 2007, 24(12), 2309-2316.
56. Zhang, Y.; Pardridge, W.M. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm. Res., 2009, 26(5), 1059-1063.
57. Xia, C.F.; Boado, R.J.; Zhang, Y.; Chu, C.; Pardridge, W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med., 2008, 10(3), 306-315.
58. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release, 2008, 128(2), 120-127.
59. Karatas, H.; Aktas, Y.; Gursoy-Ozdemir, Y.; Bodur, E.; Yemisci, M.; Caban, S.; Vural, A.; Pinarbasli, O.; Capan, Y.; Fernandez-Megia, E.; Novoa-Carballal, R.; Riguera, R.; Andrieux, K.; Couvreur, P.; Dalkara, T. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci., 2009, 29(44), 13761-13769.
60. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gursoy, R.N.; Alonso, M.J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Riguera, R.; Sargon, M.F.; Celik, H.H.; Demir, A.S.; Hincal, A.A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem., 2005, 16(6), 1503-1511.
61. Lee, H.J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther., 2000, 292(3), 1048-1052.
62. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrinand transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2009, 71(2), 251-256.
63. Mishra, V.; Mahor, S.; Rawat, A.; Gupta, P.N.; Dubey, P.; Khatri, K.; Vyas, S.P. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target, 2006, 14(1), 45-53.
64. Soni, V.; Kohli, D.V.; Jain, S.K. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J. Drug Target, 2005, 13(4), 245-250.
65. Huang, R.Q.; Qu, Y.H.; Ke, W.L.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Efficient gene delivery targeted to the brain using a transferrinconjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB. J., 2007, 21(4), 1117-1125.
66. Osborn, M.J.; McElmurry, R.T.; Peacock, B.; Tolar, J.; Blazar, B.R. Targeting of the CNS in MPS-IH using a nonviral transferrinalpha-L-iduronidase fusion gene product. Mol. Ther., 2008, 16(8), 1459-1466.
67. Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001, 46(1-3), 247-279.
68. Boado, R.J.; Zhang, Y.; Pardridge, W.M. Humanization of antihuman insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng., 2007, 96(2), 381-391.
69. Boado, R.J.; Hui, E.K.; Lu, J.Z.; Pardridge, W.M. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol., 2009, 144(2), 135-141.
70. Boado, R.J.; Zhang, Y.; Xia, C.F.; Wang, Y.; Pardridge, W.M. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2008, 99(2), 475-484.
71. Lu, J.Z.; Hui, E.K.; Boado, R.J.; Pardridge, W.M. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug. Chem., 2010, 21(1), 151-156.
72. Boado, R.J.; Zhang, Y.; Wang, Y.; Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2008, 100(2), 387-396.
73. Boado, R.J.; Pardridge, W.M. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgGGDNF fusion protein in the rhesus monkey. Drug. Metab. Dispos., 2009, 37(12), 2299-2304.
74. Pardridge, W.M.; Boado, R.J. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm. Res., 2009, 26(10), 2227-2236.
75. Boado, R.J.; Lu, J.Z.; Hui, E.K.; Pardridge, W.M. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng., 2010, 105(3), 627-635.
76. Boado, R.J.; Hui, E.K.; Lu, J.Z.; Pardridge, W.M. Drug targeting of erythropoietin across the primate blood-brain barrier with an igg molecular trojan horse. J. Pharmacol. Exp. Ther., 2010.
77. Boado, R.J.; Hui, E.K.; Lu, J.Z.; Zhou, Q.H.; Pardridge, W.M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol., 2010, 146(1-2), 84-91.
78. Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R.R.; Dagenais, C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.; Jefferies, W.A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Beliveau, R. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem., 2002, 83(4), 924-933.
79. Gabathuler, R.; Arthur, G.; Kennard, M.; Chen, Q.; Tsai, S.; Yang, J.; Schoorl, W.; Vitalis, T.Z.; Jefferies, W.A. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier. International Congress Series, 2005, 1277, 171-184.
80. Richardson, D.R.; Morgan, E.H. The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta, 2004, 1690(2), 124-133.
81. Karkan, D.; Pfeifer, C.; Vitalis, T.Z.; Arthur, G.; Ujiie, M.; Chen, Q.; Tsai, S.; Koliatis, G.; Gabathuler, R.; Jefferies, W.A. A unique carrier for delivery of therapeutic compounds beyond the bloodbrain barrier. PLoS. One, 2008, 3(6), e2469.
82. Pan, W.; Kastin, A.J.; Zankel, T.C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci., 2004, 117(Pt 21), 5071-5078.
83. Prince, W.S.; McCormick, L.M.; Wendt, D.J.; Fitzpatrick, P.A.; Schwartz, K.L.; Aguilera, A.I.; Koppaka, V.; Christianson, T.M.; Vellard, M.C.; Pavloff, N.; Lemontt, J.F.; Qin, M.; Starr, C.M.; Bu, G.; Zankel, T.C. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase. J. Biol. Chem., 2004, 279(33), 35037-35046.
84. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J.P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther., 2008, 324(3), 1064-1072.
85. Demeule, M.; Currie, J.C.; Bertrand, Y.; Che, C.; Nguyen, T.; Regina, A.; Gabathuler, R.; Castaigne, J.P.; Beliveau, R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem., 2008, 106(4), 1534-1544.
86. Drappatz, J.; Brenner, A.; Rosenfeld, S.; Mikkelsen, T.; Schiff, D.; Wen, P.; Groves, M.; Elian, K.; Fitsialos, D.; Fraitag, B.; Lawrence, B.; Castaigne, J.-P. ANG1005: New EPiC compound for the treatment of recurrent malignant glioma. Mol. Cancer. Ther., 2009, 8(12 Suppl), B160.
87. Kurzrock, R.; Gabrail, N.; Moulder, S.; Noles, C.; Smith, C.; Guo, Z.; Bouchard, D.; Churchill, W.; Bento, P.; Neale, A.; Castaigne, J.-P.; Sarantopoulos, J. ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer. Mol. Cancer Ther., 2009, 8(12 Suppl), B168.
88. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J.P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. Br. J. Pharmacol., 2008, 155(2), 185-197.
89. Thomas, F.C.; Taskar, K.; Rudraraju, V.; Goda, S.; Thorsheim, H.R.; Gaasch, J.A.; Mittapalli, R.K.; Palmieri, D.; Steeg, P.S.; Lockman, P.R.; Smith, Q.R. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res., 2009, 26(11), 2486-2494.
90. Che, C.; Yang, G.; Thiot, C.; Lacoste, M.C.; Currie, J.C.; Demeule, M.; Regina, A.; Beliveau, R.; Castaigne, J.P. New Angiopepmodified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem., 2010, 53(7), 2814-2824.
91. Ke, W.; Shao, K.; Huang, R.; Han, L.; Liu, Y.; Li, J.; Kuang, Y.; Ye, L.; Lou, J.; Jiang, C. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials, 2009, 30(36), 6976-6985.
92. Gaillard, P.J.; Brink, A.; de Boer, A.G. Diphtheria toxin receptortargeted brain drug delivery. International Congress Series, 2005, 1277, 185-198.
93. Kreuter, J. Nanoparticles--a historical perspective. Int. J. Pharm., 2007, 331(1), 1-10.
94. Ambruosi, A.; Khalansky, A.S.; Yamamoto, H.; Gelperina, S.E.; Begley, D.J.; Kreuter, J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target., 2006, 14(2), 97-105.
95. Kurakhmaeva, K.B.; Djindjikhashvili, I.A.; Petrov, V.E.; Balabanyan, V.U.; Voronina, T.A.; Trofimov, S.S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R.N. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target., 2009, 17(8), 564-574.
96. Gelperina, S.; Maksimenko, O.; Khalansky, A.; Vanchugova, L.; Shipulo, E.; Abbasova, K.; Berdiev, R.; Wohlfart, S.; Chepurnova, N.; Kreuter, J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharm. Biopharm., 2010, 74(2), 157-163.
97. Kreuter, J.; Hekmatara, T.; Dreis, S.; Vogel, T.; Gelperina, S.; Langer, K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release, 2007, 118(1), 54-58.
98. Michaelis, K.; Hoffmann, M.M.; Dreis, S.; Herbert, E.; Alyautdin, R.N.; Michaelis, M.; Kreuter, J.; Langer, K. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther., 2006, 317(3), 1246-1253.
99. Zensi, A.; Begley, D.; Pontikis, C.; Legros, C.; Mihoreanu, L.; Wagner, S.; Buchel, C.; von Briesen, H.; Kreuter, J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release, 2009, 137(1), 78-86.
100. Gao, K.; Jiang, X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm., 2006, 310 (1-2), 213-219.
101. Ujiie, M.; Dickstein, D.L.; Jefferies, W.A. p97 as a biomarker for Alzheimer disease. Front. Biosci., 2002, 7, e42-47.
102. Jefferies, W.A.; Food, M.R.; Gabathuler, R.; Rothenberger, S.; Yamada, T.; Yasuhara, O.; McGeer, P.L. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res., 1996, 712(1), 122-126.
103. Bates, K.A.; Verdile, G.; Li, Q.X.; Ames, D.; Hudson, P.; Masters, C.L.; Martins, R.N. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry., 2009, 14(5), 469-486.
104. Deane, R.; Sagare, A.; Zlokovic, B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des., 2008, 14(16), 1601-1605.
105. Ito, S.; Ueno, T.; Ohtsuki, S.; Terasaki, T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J. Neurochem., 2010, 113(5), 1356-1363.
106. Mishima, K.; Higashiyama, S.; Nagashima, Y.; Miyagi, Y.; Tamura, A.; Kawahara, N.; Taniguchi, N.; Asai, A.; Kuchino, Y.; Kirino, T. Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrain. Neurosci. Lett., 1996, 213(3), 153-156.
107. Mishima, K.; Higashiyama, S.; Asai, A.; Yamaoka, K.; Nagashima, Y.; Taniguchi, N.; Kitanaka, C.; Kirino, T.; Kuchino, Y. Heparinbinding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta. Neuropathol., 1998, 96(4), 322-328.
108. Tanaka, N.; Sasahara, M.; Ohno, M.; Higashiyama, S.; Hayase, Y.; Shimada, M. Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury. Brain Res., 1999, 827(1-2), 130-138.
109. Raab, G.; Klagsbrun, M. Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta., 1997, 1333(3), F179-199.
110. More, S.S.; Vince, R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs. J. Med. Chem., 2008, 51(15), 4581-4588.
111. Kannan, R.; Kuhlenkamp, J.F.; Jeandidier, E.; Trinh, H.; Ookhtens, M.; Kaplowitz, N. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J. Clin. Invest., 1990, 85(6), 2009-2013.
112. Kannan, R.; Chakrabarti, R.; Tang, D.; Kim, K.J.; Kaplowitz, N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res., 2000, 852(2), 374-382.
113. Zlokovic, B.V.; Mackic, J.B.; McComb, J.G.; Weiss, M.H.; Kaplowitz, N.; Kannan, R. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem. Biophys. Res. Commun., 1994, 201(1), 402-408.
114. Rip, J.; Schenk, G.J.; de Boer, A.G. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv., 2009, 6(3), 227-237.
115. Hu, Y.; Ocheltree, S.M.; Xiang, J.; Keep, R.F.; Smith, D.E. Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2. Pharm. Res., 2005, 22(8), 1281-1286.
116. Teuscher, N.S.; Keep, R.F.; Smith, D.E. PEPT2-mediated uptake of neuropeptides in rat choroid plexus. Pharm. Res., 2001, 18(6), 807-813.
117. Wang, A.J.; Jian, C.H.; Li, S.D.; Lin, Y.F.; Liu, S.J. Glutathione based delivery system. US Patent 20070141133. 2005. Industrial Technology Research Institute, Taipei, Taiwan.
118. Rip, J.; Appeldoorn, C.C.M.; Manca, F.M.; Dorland, R.; van Kregten, J.M.R.; Gaillard, P.J., Receptor-mediated delivery of drugs across the blood-brain barrier, in: Pharmacology and Toxicology of the Blood-Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. 2010: Brussels, Belgium.
119. Plum, L.; Schubert, M.; Bruning, J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab., 2005, 16(2), 59-65.
120. Herz, J. LRP: a bright beacon at the blood-brain barrier. J. Clin. Invest., 2003, 112(10), 1483-1485.
121. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev., 2002, 54(4), 561-587.
122. Moos, T.; Morgan, E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol., 2000, 20(1), 77-95.
123. Gosk, S.; Vermehren, C.; Storm, G.; Moos, T. Targeting antitransferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab., 2004, 24(11), 1193-1204.
124. Buzzi, S.; Rubboli, D.; Buzzi, G.; Buzzi, A.M.; Morisi, C.; Pironi, F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol. Immunother., 2004, 53(11), 1041-1048.
125. Anderson, P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect. Immun., 1983, 39(1), 233-238.
126. Block, K.I.; Koch, A.C.; Mead, M.N.; Tothy, P.K.; Newman, R.A.; Gyllenhaal, C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int. J. Cancer., 2008, 123(6), 1227-1239.
127. Pardridge, W.M. Biopharmaceutical drug targeting to the brain. J. Drug Target, 2010, 18(3), 157-167.
128. Lichota, J.; Skjorringe, T.; Thomsen, L.B.; Moos, T. Macromolecular drug transport into the brain using targeted therapy. J. Neurochem., 2009.
129. Koning, G.A.; Morselt, H.W.; Velinova, M.J.; Donga, J.; Gorter, A.; Allen, T.M.; Zalipsky, S.; Kamps, J.A.; Scherphof, G.L. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim. Biophys. Acta, 1999, 1420(1-2), 153-167.
130. Singh, R.; Lillard, J.W.; Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86(3), 215-223.
131. Brasnjevic, I.; Steinbusch, H.W.; Schmitz, C.; Martinez-Martinez, P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol., 2009, 87(4), 212-251.
132. Woodle, M.C.; Lasic, D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta, 1992, 1113(2), 171-199.
133. Boado, R.J.; Zhang, Y.; Wang, Y.; Pardridge, W.M. IgGparaoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm., 2008, 5(6), 1037-1043.
134. Cha, J.H.; Chang, M.Y.; Richardson, J.A.; Eidels, L. Transgenic mice expressing the diphtheria toxin receptor are sensitive to the toxin. Mol. Microbiol., 2003, 49(1), 235-240.
135. The Neurotechnology Industry 2008 Report published by NeuroInsights.